Quantification of XRCC and DNA-PK proteins in cancer cell lines and human tumors by LC–MS/MS
Author(s) -
Matthew V. Myers,
Stephen E. Maxwell,
Xiaomin Wang
Publication year - 2014
Publication title -
bioanalysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.566
H-Index - 58
eISSN - 1757-6199
pISSN - 1757-6180
DOI - 10.4155/bio.14.121
Subject(s) - hela , microbiology and biotechnology , dna , biology , serine , chemistry , biochemistry , in vitro , phosphorylation
Background: The x-ray repair cross-complementing (XRCC) proteins and a catalytic subunit of nuclear DNA-dependent serine/threonine protein kinase (DNA-PK) play important roles in cancer biology. Understanding the protein expression levels allows us to reconstruct in vivo functionality and to qualify protein biomarkers. Methods & results: XRCC and DNA-PK proteins in human cancer cells and tumor tissues have been identified and quantified by selected peptides using NanoLC and high-resolution mass spectrometry. The stable isotope-labeled full-length protein XRCC4 ([ 13 C 6 , 15 N 4 ]-arginine and [ 13 C 6 , 15 N 2 ]-lysine) uses as the internal standard. Conclusion: The assay range is 0.140–450 fmol (coefficient of variation: 25%) for XRCC4 in bovine serum albumen. The quantitative protein expression levels for XRCC and DNA-PK in HeLa, Ramos and HEK-293 cells and tumor tissues (lung and lymphoma) are reported
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom